Furthermore, studies indicate that OSMI-1, either alone or combined with doxorubicin, was effective in decreasing OGT enzyme levels and increasing apoptosis in prostate cancer cells, presenting a potential alternative treatment strategy for enhancing cancer therapy effectiveness [100]. The gene discussed is OGT; the disease is prostate carcinoma.